Therapy Detail

Therapy Name Serdemetan
Synonym
Therapy Description

Serdemetan (JNJ-26854165) is a small molecule that regulates ABCA1 expression and inhibits cholesterol transport, resulting in activation of p53 and increased cell death in p53 wild-type and mutant cells (PMID: 23820125).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Serdemetan JNJ-26854165 p53 Activator 9 Serdemetan (JNJ-26854165) is a small molecule that regulates ABCA1 expression and inhibits cholesterol transport, resulting in activation of p53 and increased cell death in p53 wild-type and mutant cells (PMID: 23820125).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
TP53 positive Advanced Solid Tumor sensitive Serdemetan Phase I Actionable In a Phase I trial, Serdemetan (JNJ-26854165) treatment increased Tp53 expression in tumor and surrogate tissue, resulted in partial response in 1.8% (1/57) and stable disease in 38.6% (22/57) of patients with advanced solid tumors (PMID: 21831953). 21831953
TP53 positive breast cancer sensitive Serdemetan Phase I Actionable In a Phase I trial, Serdemetan (JNJ-26854165) treatment induced a 102% increase of Tp53 expression in tumor tissue, resulted in partial response in a patient with breast cancer (PMID: 21831953). 21831953
Clinical Trial Phase Therapies Title Recruitment Status